Relypsa, a subsidiary of Vifor Pharma since September 1, 2016, specializes in the discovery, development, and delivery of therapeutics that utilize polymer science and other novel approaches. The company's core product is patiromer for oral suspension, the first commercialized medicine resulting from their polymer technology platform. Relypsa operates in the pharmaceutical market, primarily serving patients with hyperkalemia, a condition characterized by elevated potassium levels in the blood. The business model focuses on the development and commercialization of innovative therapeutics, generating revenue through the sale of its patented medicines. By leveraging advanced polymer science, Relypsa aims to address unmet medical needs and improve patient outcomes.

Keywords: polymer science, therapeutics, hyperkalemia, patiromer, pharmaceutical, Vifor Pharma, novel approaches, patient outcomes, medical needs, commercialization.